利妥昔单抗注射液联合CEOP方案治疗非霍奇金淋巴瘤(NHL)复发的临床疗效及其安全性  

The Clinical Efficacy and Safety of Rituximab Injection Combined with CEOP Regimen in the Treatment of Non-Hodgkin's Lymphoma(NHL)Recurrence

作　　者：谢凤玲[1] XIE Fengling(Department of Hematology,Shanxian Central Hospital,Shanxian,Shandong Province,274300 China)

机构地区：[1]单县中心医院血液内科,山东单县274300

出　　处：《中外医疗》2021年第18期8-12,共5页China & Foreign Medical Treatment

摘　　要：目的分析利妥昔单抗注射液联合CEOP方案治疗非霍奇金淋巴瘤(NHL)复发的临床疗效及其安全性。方法方便选取2017年1月—2020年1月该院收治的非霍奇金淋巴瘤(NHL)复发患者80例为研究对象,随机单双数发分为对照组40例为CEOP方案治疗,观察组患者40例接受利妥昔单抗注射液联合CEOP方案治疗,对比两种不同治疗方式下患者疾病治疗效果、安全性、疾病复发率。结果观察组患者治疗后总有效率的87.50%(35/40)高于对照组的67.50%(27/40),差异有统计学意义(χ^(2)=4.587,P<0.05);治疗前两组患者肿瘤标志物差异无统计学意义(P>0.05);治疗后观察组患者肿瘤标志物水平低于对照组,差异有统计学意义(P<0.05);治疗前两组患者免疫功能指标以及C3、C4差异无统计学意义(P>0.05);治疗后两组患者IgA差异无统计学意义(P>0.05);治疗后观察组患者C3、C4指标低于对照组,差异有统计学意义(P<0.05);观察组患者不良反应率为37.50%(15/40)和对照组的30.00%(12/40)比较差异无统计学意义(χ^(2)=0.503,P>0.05);与对照组相比,观察组患者生存期更长,且疾病复发率更低,差异有统计学意义(P<0.05)。结论为非霍奇金淋巴瘤(NHL)复发患者进行利妥昔单抗注射液联合CEOP方案治疗时可有效提升治疗效果,且安全性较高,有应用价值。Objective To analyze the clinical efficacy and safety of rituximab injection combined with CEOP regimen in the treatment of non-Hodgkin's lymphoma(NHL)recurrence.Methods Eighty patients with non-Hodgkin's lymphoma(NHL)recurrence admitted to the hospital from January 2017 to January 2020 were conveniently selected as the research objects.Randomly divided into the control group and 40 cases with CEOP regimen,the observation group of 40 patients were treated with rituximab injection combined with CEOP regimen,and the disease treatment effect,safety and disease recurrence rate of patients under two different treatment methods were compared.Results The total effective rate of patients in the observation group after treatment was 87.50%(35/40)higher than 67.50%(27/40)in the control group,the difference was statistically significant(χ^(2)=4.587,P<0.05);there were no tumor markers in the two groups before treatment,the difference was not statistically significant(P>0.05);after treatment,the level of tumor markers in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05);there was no statistically significant difference in immune function indexes and C3 and C4 between the two groups of patients before treatment(P>0.05).After treatment,there was no statistically significant difference in the IgA of the two groups of patients(P>0.05);C3 and C4 indexes of the observation group were lower than those of the control group after treatment,and the difference was statistically significant(P<0.05);the observation group of adverse reaction response rate of 37.50%(15/40)and the control group 30.00%(12/40),and the difference was not statistically significant(χ^(2)=0.503,P>0.05).Compared with the control group,the observation group had a longer survival time and lower disease recurrence rate,the difference was statistically significant(P<0.05).Conclusion Rituximab injection combined with CEOP regimen can effectively improve the therapeutic effect for patients with recurrenc

关 键 词：利妥昔单抗注射液 CEOP方案 非霍奇金淋巴瘤(NHL)复发 低血压 复发率 

分 类 号：R733.1[医药卫生—肿瘤]